Diversion Control Division, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

January 2022

Globyz Pharma, LLC; Correction (PDF) (January 24, 2022)

Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (January 21, 2022)

Daniel R. Nevarre, M.D.; Decision and Order (PDF) (January 21, 2022)

Stephen E. Owusu, D.P.M.; Decision and Order (PDF) (January 21, 2022)

Alex E. Torres, M.D.; Decision and Order (PDF) (January 21, 2022)

Tel-Pharmacy; Decision and Order (PDF) (January 19, 2022)

AARRIC, Inc. d/b/a at Cost RX; Decision and Order (PDF) (January 19, 2022)

Samson K. Orusa, M.D.; Decision and Order (PDF) (January 19, 2022)

Proposed Rule: Placement of 4-hydroxy-N,N-diisopropyltryptamine, 5-methoxy-alpha-methyltryptamine, 5-methoxy-N-methyl-N-isopropyltryptamine, 5-methoxy-N,N-diethyltryptamine, and N,N-diisopropyltryptamine in Schedule I (PDF) (January 14, 2022)

Organic Standards Solutions International, LLC (PDF) (January 14, 2022)

Curia Missouri Inc. (PDF) (January 11, 2022)

Johnson Matthey, Inc. (PDF) (January 11, 2022)

Nexus Pharmaceuticals, Inc. (PDF) (January 11, 2022)


December 2021

Gulf Med Pharmacy; Decision And Order (PDF) (December 22, 2021)

Organix Inc. (PDF) (December 21, 2021)

Timothy C. Sapp, M.D.; Decision and Order (PDF) (December 20, 2021)

Peter S. Klainer, M.D.; Decision and Order (PDF) (December 20, 2021)

Washington Bryan, M.D.; Decision and Order (PDF) (December 20, 2021)

Medical Pharmacy; Decision and Order (PDF) (December 20, 2021)

Cypress Creek Pharmacy, LLC; Order (PDF) (December 20, 2021)

SpecGX, LLC (PDF) (December 13, 2021)

Noramco, Inc. (PDF) (December 13, 2021)

Noramco Coventry LLC (PDF) (December 9, 2021)

Catalent Pharma Solutions, LLC (PDF) (December 9, 2021)

Fresenius Kabi USA, LLC (PDF) (December 9, 2021)

Tamika Mayo, M.D.; Decision and Order (PDF) (December 8, 2021)

Proposed Amendment: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I (PDF) (December 7, 2021)

Proposed Rule: Placement of Methoxetamine (MXE) in Schedule I (PDF) (December 7, 2021)

Kinetochem, LLC (PDF) (December 6, 2021)

Johnson Matthey Inc. (PDF) (December 6, 2021)

Fisher Clinical Services, Inc. (PDF) (December 6, 2021)

Final Order: Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2022 (PDF) (December 2, 2021)


November

IsoSciences, LLC (PDF) (November 29, 2021)

API Manufacturing, Inc. (PDF) (November 29, 2021)

Pisgah Laboratories Inc. (PDF) (November 29, 2021)

Noramco (PDF) (November 23, 2021)

Mylan Technologies, Inc. (PDF) (November 23, 2021)

Proposed Rule: Transfer of Electronic Prescriptions for Schedules II-V Controlled Substances between Pharmacies for Initial Filling (PDF) (November 19, 2021)

Final Rule: Designation of Methyl alpha-phenylacetoacetate, a Precursor Chemical Used in the Illicit Manufacture of Phenylacetone, Methamphetamine, and Amphetamine, as a List I Chemical (PDF) (November 18, 2021)

Pronto Pharmacy, LLC; Decision and Order (PDF) (November 18, 2021)

Proposed Rule: Regulation of Telepharmacy Practice (PDF) (November 17, 2021)

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021 (PDF) (November 15, 2021)

George Roussis, M.D.; Decision and Order (PDF) (November 5, 2021)

Larry C. Daniels, M.D.; Decision and Order (PDF) (November 5, 2021)

Proposed Rule: Removal of [\18\F]FP-CIT From Control (PDF) (November 4, 2021)

Final Order: Placement of Isotonitazene in Schedule I (PDF) (November 4, 2021)

Nanosyn Inc. (PDF) (November 3, 2021)

Groff Global (PDF) (November 3, 2021)

Fisher Clinical Services, Inc. (PDF) (November 3, 2021)


October

30-Day Notice: Recordkeeping for Electronic Prescriptions for Controlled Substances (PDF) (November 2, 2021)

Novitium Pharma LLC (PDF) (October 26, 2021)

Nicholas P. Roussis, M.D.; Decision and Order (PDF) (October 26, 2021)

Maura Tuso, D.M.D.' Decision and Order (PDF) (October 26, 2021)

Globyz Pharma, LLC (PDF) (October 26, 2021)

Indigenous Peyote Conservation Initiative (PDF) (October 26, 2021)

30-Day Notice: Recordkeeping for Electronic Prescriptions for Controlled Substances (PDF) (October 25, 2021)

Chattem Chemicals (PDF) (October 22, 2021)

Groff NA Hemplex LLC (PDF) (October 22, 2021)

Organic Consultants, LLC DBA Cascade Chemistry (PDF) (October 22, 2021)

Mycrodose Therapeutics (PDF) (October 22, 2021)

Novitium Pharma LLC (PDF) (October 22, 2021)

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2022 (PDF) (October 18, 2021)

United States Pharmaceopeial Convention (PDF) (October 12, 2021)

New Mexico Top Organics-Ultra Health (PDF) (October 7, 2021)

AndersonBrecon, Inc. (PDF) (October 7, 2021)

Caligor Coghlan Pharma Services (PDF) (October 7, 2021)

William C. Gardner, D.D.S.; Decision and Order (PDF) (October 1, 2021)

Darryl L. Henry, M.D.; Decision and Order (PDF) (October 1, 2021)

Pharmacy 4 Less; Decision and Order (PDF) (October 1, 2021)


September

Cambridge Isotope Laboratories, Inc. (PDF) (September 29, 2021)

30-Day Notice: Extension; Application for Registration Renewal DEA Forms 363, 363a (PDF) (September 28, 2021)

Groff NA Hemplex, LLC (PDF) (September 27, 2021)

PCI Synthesis (PDF) (September 24, 2021)

Cardinal Health (PDF) (September 24, 2021)

30-Day Notice: Extension; Application for Registration Renewal, DEA Forms 363, 363a (PDF) (September 23, 2021)

Salman Akbar, M.D.; Decision and Order (PDF) (September 20, 2021)

Humberto A. Florian, M.D.; Decision and Order (September 20, 2021)

Steven P. French, M.D.; Decision and Order (September 20, 2021)

Lisa M. Jones, N.P.; Dismissal of Proceedings (September 20, 2021)

Final Rule: Addition of the United States Space Force as a Registration Waiver and Registration Fee Exempt Military Entity (September 17, 2021)

Cambridge Isotope Laboratories (September 15, 2021)

Amethyst Exploration, LLC (September 13, 2021)

Eli-Elsohly Laboratories (September 13, 2021)

Cayman Chemical Company (September 13, 2021)

Aurobindo Pharma USA, Inc. (September 13, 2021)

Uvienome Linda Sakor, N.P.; Decision and Order (September 7, 2021)

Lora L. Thaxton, M.D.; Decision and Order (September 7, 2021)

Proposed Rule: Placement of Methiopropamine in Schedule I (September 2, 2021)

Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021 (September 2, 2021)


August

Chemtos, LLC (August 27, 2021)

Cambrex Charles City (August 27, 2021)

Benuvia Therapeutics Inc. (August 25, 2021)

Absolute Standards, Inc. (August 25, 2021)

Cedarburg Pharmaceuticals (August 25, 2021)

Johnson Matthey Inc. (August 25, 2021)

Galephar Pharmaceutical Research Inc. (August 19, 2021)

Chattem Chemicals, Inc. (August 19, 2021)

Catalent CTS, LLC (August 13, 2021)

Final Rule: Placement of 4,4'-DMAR in Schedule I (August 12, 2021)

PA Options for Wellness, Inc. (August 12, 2021)

Epic Pharma, LLC (August 12, 2021)

Globyz Pharma, LLC (August 12, 2021)

Cambrex High Point, Inc. (August 12, 2021)

MP Pharma Services (August 12, 2021)

Curium US, LLC (August 12, 2021)

Proposed Rule: Placement of Mesocarb in Schedule I (August 11, 2021)

Cambrex High Point, Inc. (August 5, 2021)

Purisys, LLC (August 3, 2021)

Cerilliant Corporation (August 3, 2021)

AMRI Rensselaer, Inc. (August 2, 2021)

Emergency Disaster Relief
Search for Year Round Pharmaceutical Disposal Locations.
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility